Post Polycythemia Vera Myelofibrosis (DBCOND0062303)

Identifiers

Synonyms

Post-polycythemia Vera Myelofibrosis(Post-PV MF) / Post polycythaemia vera myelofibrosis / Post-Polycythemia Vera / Post-Polycythaemia Vera / Post-polycythemia Vera (Post-PV) / Post Polycythaemia Myelofibrosis (PPV MF) / Myelofibrosis Due to and Following Polycythemia Vera / Post Polycythemia Myelofibrosis / Post Polycythemia Vera Fibrosis / Post-polycythemia Vera Related Myelofibrosis / Myelofibrosis, Post PV / Post Polycythemia-Vera Myelofibrosis / Post-Polycythemia Vera-Myelofibrosis / Post Polycythemia Vera-myelofibrosis / Post-Polycythemia Vera Myelofibrosis / Post Polycythemia Myelofibrosis (PPV MF) / Post PV MF / Post-PV MF / Post-polycythemia Vera (Post-PV) Myelofibrosis / Post-polycythemia Vera Myelofibrosis (PPV-MF) / Post-Polycythemia Vera-Myelofibrosis (PPV-MF) / Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) / Post-polycythemia Vera Myelofibrosis (Post-PV MF) / Post-Polycythemia Vera MF (Post-PV-MF) / Post-Polycythemia Vera (PV) MF / Post polycythemia vera myelofibrosis / Myelofibrosis due to and following polycythemia vera (disorder) / Myelofibrosis / Myelosis non-leukemic / Agnogenic myeloid metaplasia / Myelofibrosis (disorder) / Myelosis-non-leukaemic / Myelosis non-leukaemic

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Ruxolitinib	A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment.	Tyrosine-protein kinase JAK1target Tyrosine-protein kinase JAK2target Cytochrome P450 3A4enzyme Cytochrome P450 2C9enzyme Albumincarrier Tyrosine-protein kinase JAK3target Non-receptor tyrosine-protein kinase TYK2target Urokinase plasminogen activator surface receptortarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04217993	Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis	No drug interventions	treatment	2	completed
NCT01423058	Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis	Momelotinib	treatment	1 / 2	completed
NCT03952039	An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib	Fedratinib	treatment	3	active_not_recruiting
NCT00931762	A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis	Panobinostat	treatment	2	terminated
NCT00910728	Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases	AZD-1480	other	1	completed
NCT02101268	Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF	No drug interventions	treatment	3	completed
NCT01558739	Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)	Ruxolitinib	treatment	4	completed
NCT05714072	A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis	No drug interventions	other	1	recruiting
NCT05320198	Study of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia	No drug interventions	treatment	1 / 2	recruiting
NCT05467800	Study of Canakinumab in Patients With Myelofibrosis	No drug interventions	treatment	2	recruiting
NCT03402399	Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis	No drug interventions	other	Not Available	unknown_status
NCT01433445	Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis	Panobinostat Ruxolitinib	treatment	1	completed
NCT02966353	Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.	Ruxolitinib	treatment	2	completed
NCT06218628	Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition	Pacritinib Talazoparib	treatment	1	recruiting
NCT06073847	A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis	Fedratinib	Not Available	Not Available	recruiting
NCT04455841	INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders	Ruxolitinib	treatment	1 / 2	recruiting
NCT06327100	Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)	Ruxolitinib Tasquinimod	treatment	2	recruiting
NCT03165734	A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	Danazol Hydroxyurea Pacritinib Ruxolitinib	treatment	3	recruiting
NCT03373877	Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis	Ruxolitinib Zelavespib	treatment	1	terminated
NCT01423851	Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF	Ilginatinib	treatment	1 / 2	completed
NCT00935987	Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)	Momelotinib	treatment	1 / 2	completed
NCT04551053	To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)	Parsaclisib Ruxolitinib	treatment	3	terminated
NCT06351631	A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)	Bomedemstat IMG-7289	treatment	3	recruiting
NCT05044026	A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis	No drug interventions	Not Available	Not Available	completed
NCT04896112	A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia	No drug interventions	treatment	1	withdrawn
NCT04173494	A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)	Danazol Momelotinib	treatment	3	completed
NCT03895112	MPN-RC 118 AVID200 in Myelofibrosis	No drug interventions	treatment	1	completed
NCT03627403	Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors	No drug interventions	treatment	2	active_not_recruiting
NCT06343805	A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)	No drug interventions	treatment	1	not_yet_recruiting
NCT05882773	Asian Myeloproliferative Neoplasm (MPN) Registry	No drug interventions	Not Available	Not Available	recruiting
NCT02055781	Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia	No drug interventions	treatment	3	terminated
NCT01969838	Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis	No drug interventions	treatment	3	completed
NCT01773187	Pacritinib Versus Best Available Therapy to Treat Myelofibrosis	No drug interventions	treatment	3	terminated
NCT04551066	To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)	Parsaclisib Ruxolitinib	treatment	3	active_not_recruiting
NCT01790295	Ruxolitinib Prior to Transplant in Patients With Myelofibrosis	No drug interventions	treatment	2	terminated
NCT04717414	An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions	No drug interventions	treatment	3	active_not_recruiting
NCT04603495	Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)	No drug interventions	treatment	3	active_not_recruiting
NCT04283526	Study of Select Combinations in Adults With Myelofibrosis	No drug interventions	treatment	1	withdrawn
NCT03755518	A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib	No drug interventions	treatment	3	completed
NCT04884191	Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib	No drug interventions	treatment	2	completed
NCT04854096	Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis	No drug interventions	treatment	2	terminated
NCT05883904	Real World Evidence of Fedratinib Effectiveness in MF	No drug interventions	Not Available	Not Available	recruiting
NCT02124746	Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia	No drug interventions	treatment	2	completed
NCT01445769	Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis	No drug interventions	treatment	2	completed
NCT01236638	Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)	No drug interventions	treatment	2	completed
NCT04816565	To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)	Parsaclisib Ruxolitinib	treatment	3	not_yet_recruiting
NCT04816578	To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)	Parsaclisib Ruxolitinib	treatment	3	recruiting
NCT04745637	Managed Access Programs for INC424, Ruxolitinib	Ruxolitinib	Not Available	Not Available	available
NCT04640532	KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF	Navtemadlin TL-895	treatment	1 / 2	recruiting
NCT05280509	Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib	No drug interventions	treatment	1 / 2	recruiting
NCT06479135	Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib	No drug interventions	treatment	3	recruiting
NCT01644110	Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF	No drug interventions	treatment	1 / 2	active_not_recruiting
NCT02515630	Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	No drug interventions	treatment	2	completed
NCT03136185	Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)	No drug interventions	treatment	1 / 2	completed
NCT04878003	Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis	No drug interventions	treatment	2	recruiting
NCT03441113	Extended Access of Momelotinib in Adults With Myelofibrosis	Momelotinib	treatment	2	active_not_recruiting
NCT03935555	Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib	No drug interventions	treatment	1	terminated
NCT03662126	KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment	Navtemadlin	treatment	2 / 3	recruiting
NCT01392443	Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF	No drug interventions	treatment	2	completed